Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
06. November 2024 16:02 ET
|
Revolution Medicines, Inc.
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a...
Revolution Medicines to Participate in Upcoming Investor Conferences
05. November 2024 09:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
30. Oktober 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
25. Oktober 2024 04:15 ET
|
Revolution Medicines, Inc.
First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC Investor webcast to be held Friday, October...
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
23. Oktober 2024 06:00 ET
|
Revolution Medicines, Inc.
Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday,...
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
21. Oktober 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Blue Star Foods Issues Shareholder Letter from CEO
14. Oktober 2024 11:30 ET
|
Blue Star Foods Corp.
Balance Sheet Improvement by 50% Reduction in Liabilities Year-Over-Year Miami, FL, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”)...
Blue Star Foods’ Taste of BC Aquafarms Signs Fingerling Supply Agreement with Miracle Springs, Poised for Accelerated Growth
10. Oktober 2024 14:00 ET
|
Blue Star Foods Corp.
Major Milestone to Meet Increasing Market Demand Miami, FL, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), an integrated...
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
07. Oktober 2024 09:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
29. August 2024 08:00 ET
|
Immuneering Corporation
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference